FIG 4.
Subgroup analyses of progression-free survival by Independent Radiology Adjudication Committee in the intent-to-treat population treated with R2-CHOP versus placebo/R-CHOP. aPrespecified stratification factor. CrCl, creatinine clearance; DLBCL, diffuse large B-cell lymphoma; HR, hazard ratio; IPI, International Prognostic Index; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP.